Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

By W. Symmans, Caimiao Wei, R. Gould, Xian Yu, Ya Zhang, Mei Liu, A. Walls, A. Bousamra, Maheshwari Ramineni, Bruno Sinn and 11 more. Journal of Clinical Oncology, 2017

596 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/6d4edee3a1f546e15de75aaeac9a61772eb1f208

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Polyak
2. Lisa A. Carey

In Oncology

1. A. Garrido-Castro
2. K. Polyak
3. R. Weinberg
4. D. Hanahan

Citations in the corpus

• Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “The extent of residual disease post–neoadjuvant chemotherapy, quantified per residual cancer burden index, is a wellestablished risk factor for recurrence (137).”
• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, methodology): “Studies have also evaluated and validated the use of residual cancer burden and yP American Joint Committee on Cancer (AJCC) staging prognostic factors associated with long-term breast cancer outcomes.(86,87) There is scant evidence from randomized clinical trials to inform the question of how progr”
• Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020, unknown): “cer burden or Ki67 measurement alone (99,100).”